Citrome Leslie L
New York University School of Medicine, Department of Psychiatry, New York, NY, USA.
Drugs Today (Barc). 2004 May;40(5):445-64. doi: 10.1358/dot.2004.40.5.850492.
This is a review of the evidence for a link between exposure to second-generation antipsychotic agents and the development of type 2 diabetes mellitus. Most of this evidence comes from case series and retrospective pharmacoepidemiological studies. Exposure to second-generation antipsychotic agents increases the risk for diabetes mellitus compared to no exposure to antipsychotic drugs. The risk with second-generation antipsychotic agents compared to exposure to first-generation antipsychotics is smaller and not consistent. The differential risk among the second-generation antipsychotic agents has not yet been adequately established. Other risk factors for diabetes mellitus, such as advancing age, non-White ethnicity, family history, obesity, lack of physical activity and the diagnosis of schizophrenia, probably contribute more to the risk than exposure to any single antipsychotic drug. Clinicians are urged to manage risk by regularly monitoring all patients receiving second-generation antipsychotic agents for the emergence of diabetes mellitus.
这是一篇关于第二代抗精神病药物暴露与2型糖尿病发生之间关联的证据综述。该证据大多来自病例系列研究和回顾性药物流行病学研究。与未暴露于抗精神病药物相比，暴露于第二代抗精神病药物会增加患糖尿病的风险。与暴露于第一代抗精神病药物相比，第二代抗精神病药物的风险较小且不一致。第二代抗精神病药物之间的风险差异尚未得到充分证实。糖尿病的其他风险因素，如年龄增长、非白人种族、家族史、肥胖、缺乏体育活动以及精神分裂症诊断，可能比接触任何单一抗精神病药物对风险的影响更大。敦促临床医生通过定期监测所有接受第二代抗精神病药物治疗的患者是否出现糖尿病来管理风险。
